Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 181

1.

Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.

Theodorakis MJ, Coleman RL, Feng H, Chan J, Chiasson JL, Ge J, Gerstein HC, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Tendera M, Tuomilehto J, Yang W, Hu D, Pan C, Holman RR; ACE Study Group.

Am Heart J. 2018 May;199:170-175. doi: 10.1016/j.ahj.2017.09.001. Epub 2017 Sep 8. No abstract available.

PMID:
29754657
2.

Hedgehog Interacting Protein Promotes Fibrosis and Apoptosis in Glomerular Endothelial Cells in Murine Diabetes.

Zhao XP, Chang SY, Liao MC, Lo CS, Chenier I, Luo H, Chiasson JL, Ingelfinger JR, Chan JSD, Zhang SL.

Sci Rep. 2018 Apr 13;8(1):5958. doi: 10.1038/s41598-018-24220-6.

3.

Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study.

Gravel S, Chiasson JL, Dallaire S, Turgeon J, Michaud V.

BMJ Open. 2018 Feb 8;8(2):e020922. doi: 10.1136/bmjopen-2017-020922.

4.

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C; ACE Study Group.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7.

PMID:
28917545
5.

The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol.

Durand M, Chartrand-Lefebvre C, Baril JG, Trottier S, Trottier B, Harris M, Walmsley S, Conway B, Wong A, Routy JP, Kovacs C, MacPherson PA, Monteith KM, Mansour S, Thanassoulis G, Abrahamowicz M, Zhu Z, Tsoukas C, Ancuta P, Bernard N, Tremblay CL; investigators of the Canadian HIV and Aging Cohort Study.

BMC Infect Dis. 2017 Sep 11;17(1):611. doi: 10.1186/s12879-017-2692-2.

6.

SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial.

Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA; BARI-2D Study Group.

J Am Coll Cardiol. 2017 Jan 31;69(4):395-403. doi: 10.1016/j.jacc.2016.10.067.

7.

Effects of Changing the Amount and Source of Dietary Carbohydrates on Symptoms and Dietary Satisfaction Over a 1-Year Period in Subjects with Type 2 Diabetes: Canadian Trial of Carbohydrates in Diabetes (CCD).

Wolever TM, Chiasson JL, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA.

Can J Diabetes. 2017 Apr;41(2):164-176. doi: 10.1016/j.jcjd.2016.08.223. Epub 2016 Nov 21.

PMID:
27884550
8.

Longitudinal testing of the Information-Motivation-Behavioral Skills model of self-care among adults with type 2 diabetes.

Meunier S, Coulombe S, Beaulieu MD, Côté J, Lespérance F, Chiasson JL, Bherer L, Lambert J, Houle J.

Patient Educ Couns. 2016 Nov;99(11):1830-1836. doi: 10.1016/j.pec.2016.06.011. Epub 2016 Jun 17.

PMID:
27373961
9.

Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial.

Taleb N, Emami A, Suppere C, Messier V, Legault L, Ladouceur M, Chiasson JL, Haidar A, Rabasa-Lhoret R.

Diabetologia. 2016 Dec;59(12):2561-2571. Epub 2016 Oct 4.

PMID:
27704167
10.

Comparison of Two Continuous Glucose Monitoring Systems, Dexcom G4 Platinum and Medtronic Paradigm Veo Enlite System, at Rest and During Exercise.

Taleb N, Emami A, Suppere C, Messier V, Legault L, Chiasson JL, Rabasa-Lhoret R, Haidar A.

Diabetes Technol Ther. 2016 Sep;18(9):561-7. doi: 10.1089/dia.2015.0394. Epub 2016 Jun 29.

PMID:
27356172
11.

Socioeconomic status and glycemic control in adult patients with type 2 diabetes: a mediation analysis.

Houle J, Lauzier-Jobin F, Beaulieu MD, Meunier S, Coulombe S, Côté J, Lespérance F, Chiasson JL, Bherer L, Lambert J.

BMJ Open Diabetes Res Care. 2016 May 11;4(1):e000184. doi: 10.1136/bmjdrc-2015-000184. eCollection 2016.

12.

No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.

Huguet J, Lu J, Gaudette F, Chiasson JL, Hamet P, Michaud V, Turgeon J.

Eur J Clin Pharmacol. 2016 Aug;72(8):925-31. doi: 10.1007/s00228-016-2065-6. Epub 2016 May 5.

PMID:
27146814
13.

Response to Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.

Tang A, Rabasa-Lhoret R, Castel H, Wartelle-Bladou C, Gilbert G, Massicotte-Tisluck K, Chartrand G, Olivié D, Julien AS, de Guise J, Soulez G, Chiasson JL.

Diabetes Care. 2015 Sep;38(9):e150-1. doi: 10.2337/dc15-1091. No abstract available.

PMID:
26294785
14.

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes.

Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group.

N Engl J Med. 2015 Aug 13;373(7):610-20. doi: 10.1056/NEJMoa1415921.

15.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

16.

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.

Tang A, Rabasa-Lhoret R, Castel H, Wartelle-Bladou C, Gilbert G, Massicotte-Tisluck K, Chartrand G, Olivié D, Julien AS, de Guise J, Soulez G, Chiasson JL.

Diabetes Care. 2015 Jul;38(7):1339-46. doi: 10.2337/dc14-2548. Epub 2015 Mar 26.

PMID:
25813773
17.

Glycaemic control and self-management behaviours in Type 2 diabetes: results from a 1-year longitudinal cohort study.

Houle J, Beaulieu MD, Chiasson JL, Lespérance F, Côté J, Strychar I, Bherer L, Meunier S, Lambert J.

Diabet Med. 2015 Sep;32(9):1247-54. doi: 10.1111/dme.12686. Epub 2015 Jan 27.

PMID:
25581545
18.

Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice.

Plante E, Menaouar A, Danalache BA, Yip D, Broderick TL, Chiasson JL, Jankowski M, Gutkowska J.

Endocrinology. 2015 Apr;156(4):1416-28. doi: 10.1210/en.2014-1718. Epub 2015 Jan 6.

PMID:
25562615
19.

Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes.

Chiasson JL, Le Lorier J.

Lancet. 2014 Nov 29;384(9958):1906-7. doi: 10.1016/S0140-6736(14)60884-9. Epub 2014 Jul 31. No abstract available.

PMID:
25088436
20.

All-trans retinoic acid stimulates gene expression of the cardioprotective natriuretic peptide system and prevents fibrosis and apoptosis in cardiomyocytes of obese ob/ob mice.

Manolescu DC, Jankowski M, Danalache BA, Wang D, Broderick TL, Chiasson JL, Gutkowska J.

Appl Physiol Nutr Metab. 2014 Oct;39(10):1127-36. doi: 10.1139/apnm-2014-0005. Epub 2014 Apr 30.

PMID:
25017112

Supplemental Content

Loading ...
Support Center